{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:32:24Z","timestamp":1791837144403,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Xiamen Cell Therapy Research Center","award":["3502Z20214001"],"award-info":[{"award-number":["3502Z20214001"]}]},{"name":"the Xiamen Cell Therapy Research Center","award":["3502Z20214001"],"award-info":[{"award-number":["3502Z20214001"]}]},{"name":"the Xiamen Cell Therapy Research Center","award":["3502Z20214001"],"award-info":[{"award-number":["3502Z20214001"]}]},{"name":"the Natural Science Foundation of Fujian Province","award":["2023J011614"],"award-info":[{"award-number":["2023J011614"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The treatment of myeloid sarcoma (MS) is challenging and has not markedly improved patient prognosis. The introduction of venetoclax (VEN) has changed the treatment of MS, and venetoclax-based therapy has been described as very promising in several case reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, we analyzed the treatment outcomes of 14 patients with MS treated with venetoclax-based therapy at The First Affiliated Hospital of Xiamen University from January 2020 to October 2023<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort consisted of 7 (50%) women and 7 (50%) men with an average age of 37.5\u00a0years. Four patients (28.6%) had isolated MS de novo, 2 (14.2%) were diagnosed synchronously with AML, and 8 (57.2%) had isolated extramedullary relapse. The most common sites for MS in our cohort were the skin and lung, followed by the spinal canal, soft tissue, bone and kidney. Five patients were affected at more than three sites. Nine patients received VEN in combination with azacytidine, and 5 patients received VEN in combination with other agents. The median number of venetoclax therapies administered was 2 cycles (range: 1\u201310 cycles). A response was observed in all patients included in the study, with 8 patients (57.2%) achieving a CR and 3 patients (21.4%) achieving a PR, corresponding to an ORR (including CR and PR) of 78.6%. The median follow-up time for all patients was 13\u00a0months (range 1\u201344 months), and the 1\u00a0year OS for all patients was 67.7%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Venetoclax-based therapy shows excellent efficacy and safety in MS patients in the \u201creal world\u201d at a single institution, and a corresponding prospective study is needed to verify this conclusion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-024-01068-z","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T21:01:31Z","timestamp":1717534891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma"],"prefix":"10.1007","volume":"15","author":[{"given":"Xinyi","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siting","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"issue":"7","key":"1068_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"2","key":"1068_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1309\/AJCPO58YWIBUBESX","volume":"144","author":"CS Wilson","year":"2015","unstructured":"Wilson CS, Medeiros LJ. Extramedullary manifestations of myeloid neoplasms. Am J Clin Pathol. 2015;144(2):219\u201339.","journal-title":"Am J Clin Pathol"},{"issue":"14","key":"1068_CR3","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1182\/blood-2011-04-347229","volume":"118","author":"RL Bakst","year":"2011","unstructured":"Bakst RL, Tallman MS, Douer D, et al. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118(14):3785\u201393.","journal-title":"Blood"},{"issue":"3","key":"1068_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1309\/AJCP1ZA7HYZKAZHS","volume":"132","author":"C Campidelli","year":"2009","unstructured":"Campidelli C, Agostinelli C, Stitson R, et al. Myeloid sarcoma: extramedullary manifestation of myeloid disorders. Am J Clin Pathol. 2009;132(3):426\u201337.","journal-title":"Am J Clin Pathol"},{"key":"1068_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7819-10-13","volume":"10","author":"M Messager","year":"2012","unstructured":"Messager M, Amielh D, Chevallier C, et al. Isolated granulocytic sarcoma of the pancreas: a tricky diagnostic for primary pancreatic extramedullary acute myeloid leukemia. World J Surg Oncol. 2012;10:13.","journal-title":"World J Surg Oncol"},{"issue":"6","key":"1068_CR6","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G","volume":"48","author":"RS Neiman","year":"1981","unstructured":"Neiman RS, Barcos M, Berard C, et al. Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer. 1981;48(6):1426\u201337.","journal-title":"Cancer"},{"key":"1068_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.989366","volume":"12","author":"Z Xing","year":"2022","unstructured":"Xing Z, Zhu X, Li Z, et al. Incidence, clinical characteristics, and prognostic nomograms for patients with myeloid sarcoma: a SEER-based study. Front Oncol. 2022;12: 989366.","journal-title":"Front Oncol"},{"issue":"8","key":"1068_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.79","volume":"7","author":"G Goyal","year":"2017","unstructured":"Goyal G, Bartley AC, Patnaik MM, et al. Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. Blood Cancer J. 2017;7(8): e592.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1068_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.clml.2017.02.027","volume":"17","author":"LM Almond","year":"2017","unstructured":"Almond LM, Charalampakis M, Ford SJ, et al. Myeloid sarcoma: presentation, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk. 2017;17(5):263\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"1068_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000497210","volume":"42","author":"M Magdy","year":"2019","unstructured":"Magdy M, Abdel Karim N, Eldessouki I, et al. Myeloid sarcoma. Oncol Res Treat. 2019;42(4):219\u201324.","journal-title":"Oncol Res Treat"},{"issue":"12","key":"1068_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"5","key":"1068_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","volume":"21","author":"DA Pollyea","year":"2023","unstructured":"Pollyea DA, Altman JK, Assi R, et al. Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(5):503\u201313.","journal-title":"J Natl Compr Canc Netw"},{"key":"1068_CR13","volume":"14","author":"T Kumode","year":"2020","unstructured":"Kumode T, Rai S, Tanaka H, et al. Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. Leuk Res Rep. 2020;14: 100219.","journal-title":"Leuk Res Rep"},{"issue":"4","key":"1068_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1001\/jamaophthalmol.2020.0110","volume":"138","author":"RS Kim","year":"2020","unstructured":"Kim RS, Yaghy A, Wilde LR, et al. An iridociliochoroidal myeloid sarcoma associated with relapsed acute myeloid leukemia with FLT3-ITD mutation, treated with gilteritinib, an FLT3 inhibitor. JAMA Ophthalmol. 2020;138(4):418\u20139.","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"1068_CR15","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00277-021-04702-w","volume":"101","author":"RM Shallis","year":"2022","unstructured":"Shallis RM, Pucar D, Perincheri S, et al. Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy. Ann Hematol. 2022;101(5):1145\u20137.","journal-title":"Ann Hematol"},{"issue":"5","key":"1068_CR16","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1159\/000524878","volume":"145","author":"G Arrigo","year":"2022","unstructured":"Arrigo G, D\u2019Ardia S, Audisio E, et al. Gilteritinib in isolated breast relapse of FLT3 positive acute myeloid leukemia: a case report and review of literature. Acta Haematol. 2022;145(5):566\u201370.","journal-title":"Acta Haematol"},{"issue":"7","key":"1068_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1200\/JOP.18.00753","volume":"15","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Vos J, Chargualaf MJ. Venetoclax for refractory myeloid sarcoma. J Oncol Pract. 2019;15(7):413\u20135.","journal-title":"J Oncol Pract"},{"key":"1068_CR18","volume":"17","author":"N Mandhan","year":"2022","unstructured":"Mandhan N, Yassine F, Li K, et al. Bladder myeloid sarcoma with TP53 mutated myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndrome: response to decitabine-venetoclax regimen. Leuk Res Rep. 2022;17: 100286.","journal-title":"Leuk Res Rep"},{"issue":"2","key":"1068_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00280-021-04356-5","volume":"89","author":"A Condorelli","year":"2022","unstructured":"Condorelli A, Matteo C, Leotta S, et al. Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement. Cancer Chemother Pharmacol. 2022;89(2):267\u201370.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1068_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/10781552221110826","volume":"29","author":"F De la Garza-Salazar","year":"2023","unstructured":"De la Garza-Salazar F, Pe\u00f1a-Lozano SP, G\u00f3mez-Almaguer D, et al. Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor. J Oncol Pharm Pract. 2023;29(2):493\u20137.","journal-title":"J Oncol Pharm Pract"},{"key":"1068_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1068_CR22","doi-asserted-by":"publisher","first-page":"6752","DOI":"10.1038\/s41598-022-10831-7","volume":"12","author":"H Zhao","year":"2022","unstructured":"Zhao H, Dong Z, Wan D, et al. Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma. Sci Rep. 2022;12(1):6752.","journal-title":"Sci Rep"},{"issue":"1","key":"1068_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12905-021-01328-y","volume":"21","author":"A Shatilova","year":"2021","unstructured":"Shatilova A, Girshova L, Zaytsev D, et al. The myeloid sarcoma treated by venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report. BMC Womens Health. 2021;21(1):184.","journal-title":"BMC Womens Health"},{"issue":"11","key":"1068_CR24","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1080\/10428194.2020.1779255","volume":"61","author":"W Pan","year":"2020","unstructured":"Pan W, Zhao X, Shi W, et al. Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation. Leuk Lymphoma. 2020;61(11):2756\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"1068_CR25","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1080\/10428194.2020.1742908","volume":"61","author":"S Otoukesh","year":"2020","unstructured":"Otoukesh S, Zhang J, Nakamura R, et al. The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. Leuk Lymphoma. 2020;61(8):2020\u20133.","journal-title":"Leuk Lymphoma"},{"key":"1068_CR26","doi-asserted-by":"publisher","DOI":"10.1159\/000534026","author":"S Bae","year":"2023","unstructured":"Bae S, Sa S, Park S, et al. Limited efficacy of venetoclax combination regimens in acute myeloid leukemia with extramedullary relapse. Acta Haematol. 2023. https:\/\/doi.org\/10.1159\/000534026.","journal-title":"Acta Haematol"},{"issue":"6","key":"1068_CR27","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1111\/bjh.18961","volume":"202","author":"M Belhadj","year":"2023","unstructured":"Belhadj M, Burroni B, Kosmider O, et al. Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: a French retrospective multi-centric observational study. Br J Haematol. 2023;202(6):e50\u20133.","journal-title":"Br J Haematol"},{"issue":"21","key":"1068_CR28","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1002\/cncr.34459","volume":"128","author":"S Ball","year":"2022","unstructured":"Ball S, Knepper TC, Deutsch YE, et al. Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations. Cancer. 2022;128(21):3880\u20137.","journal-title":"Cancer"},{"issue":"1","key":"1068_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41409-020-0984-4","volume":"56","author":"JJ Frietsch","year":"2021","unstructured":"Frietsch JJ, Hunstig F, Wittke C, et al. Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. Bone Marrow Transpl. 2021;56(1):101\u20139.","journal-title":"Bone Marrow Transpl"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01068-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01068-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01068-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T09:22:02Z","timestamp":1717579322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01068-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01068-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"7 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted in accordance with international guidelines and the ethical standards outlined in the Declaration of Helsinki. This study was approved by the Medical Ethics Committee of The First Affiliated Hospital of Xiamen College and medical records that were used in this research were obtained from previous clinical encounters and met the four principles governing the waiver of informed consent. The data are anonymous, and the requirement for informed consent was therefore waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}